Abrégé

A transcription overriding cassette (TORC) composed for the expression of at least one gene of interest, characterised in that the TORC comprises two parts, one being a first DNA sequence comprising a strong constitutive promoter DNA sequence having at least 50% nucleotide identity with the promoter DNA sequence according to SEQ ID 6 and one being a second DNA sequence having at least 50% nucleotide identity with SEQ ID 23. The first DNA sequence is located directly before the second DNA sequence within the TORC and the first and second DNA sequences are connected directly to each other within the complete sequence of the TORC or are separated from each other within the complete sequence of the TORC by DNA sequences of DNA restriction cleavage sites.

Classes IPC  ?

• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora

Abrégé

The present invention refers to a diagnostic method for the ex-vivo prognosis, prediction or risk stratification for mortality, disease outcome or ICU admission of a patient who has been diagnosed with community acquired pneumonia (CAP) comprising the steps of i) providing a sample that has been obtained from the patient and ii) analysing the expression level of at least one nucleic acid in the sample, wherein the patient's prognosis, prediction or risk stratification is determined according to the expression levels of the at least one nucleic acid. The at least on nucleic acid is selected from a gene signature comprising biomarkers as identified in the present invention. In further aspects the present invention also refers to the nucleic acids of the gene signature and their use for prognosis and risk stratification. Finally, the present invention also refers to a diagnostic kit for performing the method of the invention.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

Provided herein are methods for treating pulmonary hypertension. The methods include formulation of stable and highly concentrated imatinib solutions, selection of inhalers and nebulizers capable of aerosolizing such stable and highly concentrated imatinib solutions and administering to a subject an effective dose of imatinib, wherein imatinib solution is aerosolized using a nebulizer and inhaled by the subject. In preferred embodiments, the nebulizer is selected from the group of soft mist inhalers, such as the Medspray™ wet aerosol inhaler or the Respimat™. Provided herein are methods for treating pulmonary hypertension. The methods include formulation of stable and highly concentrated imatinib solutions, selection of inhalers and nebulizers capable of aerosolizing such stable and highly concentrated imatinib solutions and administering to a subject an effective dose of imatinib, wherein imatinib solution is aerosolized using a nebulizer and inhaled by the subject. In preferred embodiments, the nebulizer is selected from the group of soft mist inhalers, such as the Medspray™ wet aerosol inhaler or the Respimat™. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing stable and highly concentrated imatinib solutions (b) providing an aerosol producing device capable of aerosolizing such stable and highly concentrated imatinib solutions (b) administering to the patient an effective dose of imatinib by inhalation.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE

Abrégé

The invention relates to a method for determining a score value (S) for the likelihood of the presence of a pulmonary hypertension (PH) in a person (P).

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

Provided are diamondoid salts, electrolytes comprising the diamondoid salts, and electrochemical devices incorporating the diamondoid salts or electrolytes. In embodiments, an electrolyte for an electrochemical device comprises a metallic salt and a diamondoid salt, the diamondoid salt comprising a diamondoid-functionalized cationic core and a counter anion, the diamondoid-functionalized cationic core comprising a cationic core and a diamondoid group covalently bound to the cationic core.

Classes IPC  ?

• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
• C25B 3/26 - Réduction du dioxyde de carbone
• H01M 10/0567 - Matériaux liquides caracterisés par les additifs
• H01M 10/0568 - Matériaux liquides caracterisés par les solutés

Abrégé

The invention relates to a cleaning device (1) for removal of biofilms in a dental region (2). The cleaning device comprises a connection (10) for supply of fluid and of electrical energy, a shaft (20) through which fluid is able to flow, and, arranged within the shaft, first and second electrical lines (40, 50) having first and second electrodes (410, 510), respectively. The cleaning device further comprises a tip (60), wherein the tip is designed to be connectable to the second electrical line (50) such that it can serve as second electrode (510). Current is able to flow in the region arranged between the first electrode and the second electrode and irrigated by fluid, such that reactive compounds and/or gases can form in the fluid, which remove biofilms from the dental region (2) that is to be cleaned.

Classes IPC  ?

• A61C 17/02 - Dispositifs de rinçage ou insufflateurs d'air, p. ex. utilisant des jets de fluide
• A61L 2/03 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques du courant électrique, p. ex. électrolyse
• A61C 17/20 - Dispositifs à entraînement mécanique pour nettoyer ou pour polir utilisant des ondes ultrasonores

Abrégé

The invention relates to an attachment (100) for cleaning and removing a biofilm from implants, comprising at least: • a connector (1) for connecting to a base unit (200) for providing fluid and electrical energy, having an adapter (1a) for introducing fluid in order to supply the attachment (100) with fluid from the base unit (200), and an adapter (1b) for introducing electrical energy from the base unit (200) into the attachment (100); • a rod (2) through which a fluid can flow, having at least one first opening (2a) in the direction of the implant (500) to be cleaned and a second opening (2b) for connecting the rod (2) to the adapter (1a) of the connector (1), wherein there is a cavity (2c) between the at least one first opening (2a) and the second opening (2b), through which a fluid can freely flow, wherein the rod (2) through which a fluid can flow can be connected to the connector (1) such that a fluid can flow through the adapter (1a) via the second opening (2b) and the cavity (2c) through the at least one first opening (2a); • wherein the rod (2) comprises an integrated first electrical conductor (3) with an exposed cathode (3a), which can be connected to the negative pole of the adapter (1b) of the connector (1) in such a way that current can flow between the base unit (200) and an implant (500) via the attachment (100). The attachment (100) further comprises a second electrical conductor (4) with an anode (4a), which can be connected to the positive pole of the adapter (1b) of the connector (1) in such a way that current can flow via an implant from the first electrical conductor to the electrical conductor (4).

Classes IPC  ?

• A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
• A61L 2/03 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques du courant électrique, p. ex. électrolyse
• A61C 17/00 - Dispositifs pour nettoyer, polir, rincer ou sécher les dents, les cavités dentaires ou les prothèsesAppareils pour enlever la saliveRéceptacles pour les crachats à usage dentaire

Abrégé

The mixture of substances according to the invention for producing a composite material comprises the following components: water, gelling agent with a mass fraction of 0.01% to 6%, algae with a mass fraction of 0.01% to 0.8%, cyanobacteria with a mass fraction of 0.01% to 0.8% and chitin with a mass fraction of 0.05% to 3.0%. The composite material produced from this mixture of substances can be processed into any shapes and can be used for example to produce printed circuit boards, packaging material, paper or as a gel-like dressing material or applicator for drugs on skin surfaces.

Classes IPC  ?

• C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
• C08J 5/18 - Fabrication de bandes ou de feuilles
• C08L 5/12 - Agar-agarSes dérivés
• C08L 89/00 - Compositions contenant des protéinesCompositions contenant leurs dérivés

Abrégé

1+x1-x2232323122-alcohol mixture or a water/acetone mixture.

Classes IPC  ?

• H01M 4/04 - Procédés de fabrication en général
• H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
• H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
• C01G 53/00 - Composés du nickel
• H01M 4/131 - Électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p. ex. LiCoOx
• H01M 4/1391 - Procédés de fabrication d'électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p. ex. LiCoOx

Abrégé

1−x−y-zyz22, and the surfaces of the core particles exhibit a coating comprising at least one polycationic organic polymer or at least one polyanionic organic polymer.

Classes IPC  ?

• H01M 4/04 - Procédés de fabrication en général
• H01M 4/131 - Électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p. ex. LiCoOx
• H01M 4/1391 - Procédés de fabrication d'électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p. ex. LiCoOx
• H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
• H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
• H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
• H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
• H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
• H01M 10/0562 - Matériaux solides
• H01M 10/0565 - Matériaux polymères, p. ex. du type gel ou du type solide
• H01M 10/0568 - Matériaux liquides caracterisés par les solutés
• H01M 10/0569 - Matériaux liquides caracterisés par les solvants

Abrégé

A beverage comprising at least one fermentative extract, characterized in that the fermentative extract is obtained from at least one agricultural secondary flow, the at least one agricultural secondary flow being an agricultural secondary flow from the production of spices, for example a saffron secondary flow that comprises entire flowers and/or petals and/or anthers and/or stigmata of the saffron plant.

Classes IPC  ?

• A23F 3/40 - Arômes de théHuile de théAromatisation du thé ou d'extraits de thé
• A23L 27/24 - Épices, agents aromatiques ou condiments synthétiques préparés par fermentation
• C12C 5/02 - Produits d'addition pour la bière
• A23F 3/10 - Fermentation par addition de micro-organismes ou d'enzymes
• A23L 2/38 - Autres boissons non alcoolisées
• C12G 1/022 - FermentationTraitement microbiologique ou enzymatique
• C12G 3/02 - Préparation d'autres boissons alcoolisées par fermentation
• A23L 2/52 - Addition d'ingrédients
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

Described are a coated particulate material for use in an electrode of an electrochemical cell and a process for preparing said coated particulate material, an electrode comprising said coated particulate material, an electrochemical cell comprising said coated particulate material, and a use of said coated particulate material for preparing an electrode for use in an electrochemical cell.

Classes IPC  ?

• H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
• H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
• H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
• H01M 10/0569 - Matériaux liquides caracterisés par les solvants
• H01M 10/42 - Procédés ou dispositions pour assurer le fonctionnement ou l'entretien des éléments secondaires ou des demi-éléments secondaires
• H01M 10/48 - Accumulateurs combinés à des dispositions pour mesurer, tester ou indiquer l'état des éléments, p. ex. le niveau ou la densité de l'électrolyte

Abrégé

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

Classes IPC  ?

• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora

Abrégé

30322433 and CAS number 2222941-37-7. Synonyms are CCS1477, inobrodib, inobrodibum, CCS-1477, CCS 1477, CBP-IN-1 or CBP/p300-IN-4.

Classes IPC  ?

• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 9/12 - Antihypertenseurs
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

283343 3 and the CAS registry number 1613695-14-9. The synonyms are SGC-CBP30, SGCCBP30, or SGC CBP30

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

Provided herein are methods for treating pulmonary hypertension. The methods include formulation of stable and highly concentrated imatinib solutions, selection of inhalers and nebulizers capable of aerosolizing such stable and highly concentrated imatinib solutions and administering to a subject an effective dose of imatinib, wherein imatinib solution is aerosolized using a nebulizer and inhaled by the subject. In preferred embodiments, the nebulizer is selected from the group of soft mist inhalers, such as the Medspray™ wet aerosol inhaler or the Respimat™. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing stable and highly concentrated imatinib solutions (b) providing an aerosol producing device capable of aerosolizing such stable and highly concentrated imatinib solutions (b) administering to the patient an effective dose of imatinib by inhalation.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/12 - AérosolsMousses
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 9/08 - Vasodilatateurs pour des indications multiples

Abrégé

xyzyy) (z < x). The second gas is transported to a sulphur precipitation chamber in which sulphur is precipitated. The process makes it possible to obtain pure tellurium from CdTe in an energy-saving, cost-saving and faster way. The invention also relates to a plant suitable for carrying out the process according to the invention.

Classes IPC  ?

• C01B 19/02 - Sélénium ou tellure élémentaire

Abrégé

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject an effective amount of iloprost on demand or as rescue medication (also referred to as pro re nata, PRN), wherein iloprost is administered to the subject via inhalation using a portable soft mist inhaler. In preferred embodiments, the soft mist inhaler is the RespimatTMor the MedsprayTM wet aerosol inhaler. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing a portable and pre-filled soft mist inhaler adapted for delivering an effective amount of iloprost; and (b) administering to the patient the effective amount of iloprost by inhalation on an as-needed basis.

Classes IPC  ?

• A61K 31/5578 - Eicosanoïdes, p. ex. leucotriènes ayant un système cyclique pentalène, p. ex. carbacycline, iloprost
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 9/08 - Vasodilatateurs pour des indications multiples
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention provides a new system, resp. method, of genetic modification, called ACIT (Alphaproteobacteria chromosomally inserting transcription-control cassette). The invention, however, is not limited to use in Alphaproteobacteria. The modification can be implemented within the bacterial chromosome and therefore permanently implemented within the microorganism.

Classes IPC  ?

• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
• C12N 15/72 - Systèmes d'expression utilisant des séquences régulatrices dérivées de l'opéron lac
• C12N 15/67 - Méthodes générales pour favoriser l'expression

Abrégé

NNNN'-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

Classes IPC  ?

• A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/452 - Dérivés de pipéridinium
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• C07D 211/56 - Atomes d'azote
• C07D 211/58 - Atomes d'azote liés en position 4

Abrégé

The invention is about a device, for example a microsphere, constructed for the slow release of pharmaceutically or microbiologically active substances and its use for disinfection of wounds/niches/periodontal pockets.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/50 - Microcapsules
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 31/05 - Phénols
• A61K 31/14 - Composés d'ammonium quaternaire, p. ex. édrophonium, choline
• A61K 31/155 - Amidines (), p. ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
• A61K 31/4425 - Dérivés de pyridinium, p. ex. pralidoxime, pyridostigmine
• A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
• A61K 33/18 - IodeSes composés
• A61K 33/20 - Chlore élémentaireComposés minéraux libérant du chlore
• A61K 33/32 - ManganèseSes composés
• A61K 33/38 - ArgentSes composés
• A61K 33/40 - Peroxydes
• A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
• A61P 11/02 - Agents rhinologiques, p. ex. décongestionnants
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/02 - Antiseptiques locaux
• A61P 31/04 - Agents antibactériens

Abrégé

The subject matter of the invention relates to a tetrapeptide which binds to the ZIP9 receptor for the treatment of osteoporosis, myodegenerative diseases, and male infertility. The invention also relates to the use of the tetrapeptide as a nutritional and feed supplement and to the in-vitro use for growing muscle mass (in-vitro meat production). It is a tetrapeptide consisting of four amino acids which are chemically interlinked by means of peptide bonds, characterised in that it contains the amino acids IAPG (SEQ ID 1) and binds to the androgen receptor ZIP9.

Classes IPC  ?

• A61K 38/07 - Tétrapeptides
• C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala
• A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
• A61P 5/26 - Androgènes

Abrégé

A method for determining contractility independent of load Ees of a ventricle of a person is provided. The chronological profile of blood pressure during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) is first determined for a at least one ventricle over at least one period of a person's heartbeat. The at least one resulting pressure curve is then calibrated and normalized, and then the end-systolic pressure is determined from this calibrated, normalized pressure curve. The profile of blood volume over time is determined during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) for a ventricle over at least one period of a person's heartbeat, to determine the end-systolic volume Ves. The intercept VO is then determined from this end-systolic volume Ves, and contractility independent of load Ees of an examined ventricle of a person is calculated as a slope from the end-systolic pressure Pes, the end-systolic volume Ves, and the intercept V0.

Classes IPC  ?

• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• A61B 8/04 - Mesure de la pression sanguine
• A61B 8/06 - Mesure du débit sanguin
• A61B 8/08 - Applications cliniques

Abrégé

The present invention relates to a comprehensive method for analysing various chemical compounds from samples after performance of at least one metabolism process. The sample is placed on a carrier and various metabolism processes are simulated, e.g. a metabolic process from the human digestive tract from the mouth, stomach and intestine region or the gastrointestinal region. By chromatographic separation, the sample and/or metabolism products are separated and can be detected and analysed individually or jointly. By bringing suspended or adherent cells into contact with the sample or the metabolism products, a conclusion can also be made as to the biological action. The method can be performed quickly, easily and also by means of automation.

Classes IPC  ?

• C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
• G01N 30/90 - Chromatographie sur plaque, p. ex. chromatographie en couche mince ou chromatographie sur papier

Abrégé

A bacterial strain comprising one or more vectors encoding a) one or more enzymes to produce one or more terpene precursors; and b) a fungal terpene synthase (FTPS). The present invention also relates to a method of producing a terpenoid comprising a) culturing the bacterial strain described herein in an expression medium; and b) isolating the terpenoid from said expression medium.

Classes IPC  ?

• C12N 9/88 - Lyases (4.)
• C12N 9/10 - Transférases (2.)
• C12N 9/90 - Isomérases (5.)
• C12P 5/00 - Préparation des hydrocarbures
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger

Abrégé

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gramnegative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• A61P 31/04 - Agents antibactériens
• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides

Abrégé

The application describes a polycistronic expression cassette comprising two or more coding sequences each separated by a coding sequence encoding a self-cleaving peptides sequence. Self-cleaving peptides cause a ribosomal skipping event allowing a polycistronic translation of two or more coding sequences under the control of a single promoter element. One or more of said coding sequences encode one or more lethal gene product(s) making this expression cassette a lethality system. The expression cassette is under the control of a single repressible promoter. The application also describes an expression construct, which further comprises a second expression cassette. The second expression cassette optionally encodes one or more male determining gene(s). Also, the application describes a transgenic insect comprising this polycistronic expression cassette or expression construct. The transgenic insect is a crop pest insect or a disease transmitting insect. The application also describes the use of a transgenic insect according to the invention for controlling reproduction in an insect population of interest. Furthermore, the application provides a method of controlling reproduction in an insect population of interest.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The invention relates to an apparatus (10) for producing ion beams of adjustable ion beam profiles. Said apparatus comprises at least one plasma vessel (20) of an ion source with at least two ion optics (25, 26) and an ion optics changer (28). The ion optics changer (28) is designed in such a way that it can move the ion optics (25, 26) between two positions, the ion beam emitted from the plasma vessel of the ion source (20) passing a first ion optics (25) in a first position and alternatively passing a second ion optics (26) in at least one other position.

Classes IPC  ?

• H01J 37/04 - Dispositions des électrodes et organes associés en vue de produire ou de commander la décharge, p. ex. dispositif électronoptique, dispositif ionoptique
• H01J 37/08 - Sources d'ionsCanons à ions
• H01J 37/147 - Dispositions pour diriger ou dévier la décharge le long d'une trajectoire déterminée
• F03H 1/00 - Utilisation du plasma pour produire une poussée propulsive par réaction

Abrégé

Agrocybe aegeritaAgrocybe pediadesAgrocybe pediades.

Classes IPC  ?

• C12P 5/00 - Préparation des hydrocarbures
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

The invention relates to an apparatus for mass-spectrometric analysis and three-dimensional imaging of the surface of a sample, comprising at least one energy source for desorbing and/or ionizing atoms from the surface of a sample, a displacement stage, and a light source. Further, it comprises an interface in order to be able to interchange data with a mass spectrometer such that measurement data can be transmitted from a mass spectrometer to the evaluation unit via the interface such that the chemical composition of the measurement point can be determined by the evaluation unit. The surface of a sample can be captured in three dimensions and the topography of this surface can be determined by the evaluation unit.

Classes IPC  ?

• H01J 49/16 - Sources d'ionsCanons à ions utilisant une ionisation de surface, p. ex. émission thermo-ionique ou photo-électrique
• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
• H01J 49/40 - Spectromètres à temps de vol

Abrégé

The invention relates to a zinc electrode (1) for use in a zinc-oxygen battery or NiOOH-zinc battery, comprising a first layer (20) of zinc and/or zinc oxide. The carbon electrode (1) further has a second layer (30), which is designed such that it can be used as an anion exchanger and is also permeable to OH- ions.

Classes IPC  ?

• H01M 4/24 - Électrodes pour accumulateurs alcalins
• H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
• H01M 12/06 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type élément primaire avec une électrode métallique et une électrode à gaz
• H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
• H01M 10/30 - Accumulateurs au nickel

Abrégé

The invention relates to nanoparticles for the administration of the active ingredient by inhalation, the active ingredient being selected from the list comprising paclitaxel, docetaxel and SB-T-1214, comprising PLGA, PVA, TPGS, PLA, and for the treatment of pulmonary hypertension. The particles are distinguished by a high degree of loading and high stability in the process of nebulization by means of a nebulizing device.

Classes IPC  ?

• A61K 9/50 - Microcapsules
• A61K 9/51 - Nanocapsules

Abrégé

The present invention relates to a method for producing a vitamin- and protein-rich product, to a food product containing the vitamin- and protein-rich product, and to a nutrient medium appropriate for said method on the basis of agricultural tributaries or food tributaries.

Classes IPC  ?

• C12N 1/14 - ChampignonsLeurs milieux de culture
• C12N 1/20 - BactériesLeurs milieux de culture
• C12P 39/00 - Procédés faisant intervenir simultanément des micro-organismes de différents genres dans le même procédé
• C12P 19/42 - Cobalamines, c.-à-d. vitamines B12, facteur LLD

Abrégé

The invention relates to an apparatus for mass-spectrometric analysis and three-dimensional imaging of the surface of a specimen, comprising at least one energy source 20 for desorbing and/or ionizing atoms on the surface of a specimen, a displacement stage 1, and a light source 8, 10. Moreover, it comprises a control unit 30 for controlling the displacement stage 1 in such a way that the surface of a specimen can be irradiated in a punctiform manner by the energy source 20, 10 and the light source 8, 10, either step-by-step or in a continuous movement. Further, it comprises an interface 50 in order to be able to interchange data with a mass spectrometer such that measurement data from a mass spectrometer can be transmitted via the interface 50 to the evaluation unit, and so the chemical composition of the measurement point 60 can be determined by the evaluation unit 40. Further, it comprises an optical system 3, a light detector 4 and an evaluation unit 40. Here, the light source 8, 10, the optical system 3 and the light detector 4 interact in such a way that a measurement point 60 can be produced on a specimen by the light source 8, 10 by way of an optical system and light that is reflected or scattered by the measurement point 60 can be captured by the light detector 4 with an optical system 3 disposed upstream thereof. Hence, it is possible to capture the surface of a specimen in three dimensions and the topography of this surface can be determined by the evaluation unit 40.

Classes IPC  ?

• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
• H01J 49/16 - Sources d'ionsCanons à ions utilisant une ionisation de surface, p. ex. émission thermo-ionique ou photo-électrique

Abrégé

The invention describes a new method for in vivo measurement and control of intraocular VEGF concentration using bioluminescence resonance energy transfer (BRET) of a VEGF-binding biosensor. Furthermore, the method is suitable for highly sensitive in vitro determination of VEGF concentration from a small sample volume.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 49/00 - Préparations pour examen in vivo
• G01N 33/542 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p. ex. extinction de fluorescence

Abrégé

The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01N 63/10 - Animaux Substances produites par des animaux ou obtenues à partir de ceux-ci
• A01N 57/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques du phosphore comportant des liaisons phosphore-oxygène ou des liaisons phosphore-soufre contenant des radicaux hétérocycliques
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A01N 61/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des substances de composition non connue ou indéterminée, p. ex. des substances caractérisées uniquement par leur mode d'action
• A01N 65/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant du matériel provenant d'algues, de lichens, de bryophytes, de champignons multicellulaires ou de plantes, ou leurs extraits

Abrégé

The present invention relates to a Statistical method of assessing whether a subject suffers from Cancer or is prone to suffering from Cancer, said method comprising the step of performing at least one Statistical algorithm for Classification and for regression on measurement data of the subject, wherein the measurement data of the subject comprises at least one of the following: a value of GATA6 Em isoform in at least one sample taken from the subject, a value NKX2-1 Em isoform in said at least one sample, a value of GATA6 Ad isoform in said at least one sample, NKX2-1 Ad isoform in said at least one sample; and wherein at least one of the following is used as at least one classifier or a component of at least one classifier in the Statistical method: GATA6 Em isoform, NKX2-1 Em isoform, GATA6 Ad isoform, NKX2-1 Ad isoform, ratio of GATA6 Em isoform / GATA6 Ad isoform, ratio of NKX2- 1 Em isoform / NKX2-1 Ad isoform.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to an ion drive for a spacecraft, in particular for a satellite, comprising a reservoir with fuel; an ionization chamber connected to the reservoir; a generator for producing an electrostatic, magnetostatic and/or electromagnetic field the interior of the ionization chamber, wherein the field is suitable for ionizing the fuel; and a charge-carrier acceleration system for producing an electric field suitable for accelerating the ionized fuel, wherein the fuel contains a diamondoid. Moreover, the invention relates to a spacecraft comprising an ion drive, a method for operating an ion drive and the use of diamandoid as fuel for an ion drive.

Classes IPC  ?

• F03H 1/00 - Utilisation du plasma pour produire une poussée propulsive par réaction

Abrégé

The invention relates to a coating of glass with thermochromic vanadium dioxide. The coloration of the vanadium dioxide is shifted from bronze to neutral (colorless) by a doping with alkaline earth metals, for example Ca, Sr and Br. The thermochromic effect is maintained at the same time.

Classes IPC  ?

• B32B 9/00 - Produits stratifiés composés essentiellement d'une substance particulière non couverte par les groupes
• B32B 13/00 - Produits stratifiés composés essentiellement d'une substance à prise hydraulique, p. ex. du béton, du plâtre, du ciment, ou d'autres matériaux entrant dans la construction
• B32B 19/00 - Produits stratifiés composés essentiellement de fibres ou particules minérales naturelles, p. ex. d'amiante, de mica
• C03C 17/06 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement par des métaux
• C03C 17/34 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement avec au moins deux revêtements ayant des compositions différentes
• C03C 17/245 - Oxydes par dépôt à partir d'une phase vapeur
• C23C 14/34 - Pulvérisation cathodique
• H01L 31/0216 - Revêtements
• C09K 9/00 - Substances devenant sombres, c.-à-d. substances pour lesquelles la gamme de longueurs d'onde absorbées est modifiée par excitation avec une énergie sous une forme quelconque

Abrégé

The invention relates to an atomizer system 100 comprising a spray head and a spray chamber 18 that can be gas-sealingly connected to the spray head. In a part facing the spray chamber 18 the spray head 1 has a tapered portion forming a nozzle 17 for atomizing liquid with gas. The spray head 1 thus has a two-phase nozzle with internal mixing.

Classes IPC  ?

• B05B 7/04 - Pistolets pulvérisateursAppareillages pour l'évacuation avec des dispositifs permettant le mélange de liquides ou d'autres matériaux fluides avant l'évacuation
• B05B 15/12 - Cabines de pulvérisation
• B05B 17/04 - Appareils de pulvérisation ou d'atomisation de liquides ou d'autres matériaux fluides, non couverts par les autres groupes de la présente sous-classe opérant suivant des procédés particuliers
• F15D 1/08 - Action sur l'écoulement des fluides des jets sortant d'un orifice
• B05D 1/02 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces réalisés par pulvérisation
• B05B 7/12 - Pistolets pulvérisateursAppareillages pour l'évacuation agencés pour commander le volume débité, p. ex. à l'aide de passages réglables

Abrégé

The invention relates to the use of esters of saturated short- and medium-chain fatty acids for the prophylaxis and therapy of diseases and cosmetic problems in humans and animals caused or sustained involving Malassezia yeasts.

Classes IPC  ?

• A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
• A61K 31/23 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01N 61/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des substances de composition non connue ou indéterminée, p. ex. des substances caractérisées uniquement par leur mode d'action

Abrégé

The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to gas sensors and in particular a gas sensor system comprising a plurality of gas sensor elements, having the possibility of simultaneously detecting a plurality of different gases. The gas sensors, which are of a new type, combined in a gas sensor system, enable the simultaneous detection of different gases while the media separation is maintained between the detection and evaluation unit and the sensor chip for use in chemically aggressive or explosive gases or gas mixtures. In particular, semiconductor nanostructures that emit photoluminescence (PL) are used as sensor elements.

Classes IPC  ?

• G01N 21/64 - FluorescencePhosphorescence
• B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
• G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur

Abrégé

Inhalation is one of the most important methods of administration of active ingredients, for example in the treatment of respiratory disorders or in anaesthesia. A disadvantage of the current prior art is that not all solutions or suspensions can be nebulized with a standard nebulizer so as to result in a particle size distribution suitable for inhalation treatment in the aerosol produced. The invention therefore relates to a method for nebulizing a solution or colloid to form aerosol particles, wherein the solution or colloid contains at least one additive, the additive being a low molecular weight compound or a polyether or a polysorbate or a modified PVA, and aerosol-physical parameters of the particles formed by nebulization of the solution or colloid are adjusted via the concentration of the additive in the solution or of the colloid. The invention further relates to an aerosol obtainable by this method for pulmonary administration in a patient for diagnosis or treatment of a disorder.

Classes IPC  ?

• A61K 47/02 - Composés inorganiques
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

The invention relates to an optical pH value sensor having a nanowire structure and applied electrochemical potential, wherein the photoluminescence intensity of the nanowires is detected in a spatially resolved manner and then the pH values are determined by means of the calibration data.

Classes IPC  ?

• G01N 27/416 - Systèmes
• G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c.-à-d. ISFETS ou CHEMFETS
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/80 - Indication de la valeur du pH
• B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
• G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique

Abrégé

The molecule NAD and the diastereomer thereof ß-NAD have a muscle-relaxant effect on the musculature of the airways, particularly on the bronchial musculature. Therefore NAD and the diastereomer thereof ß-NAD open up a new approach for the therapy and prophylaxis of a number of diseases, disorders and conditions in which the concentration of free calcium in the muscle cells of the airway musculature is abnormally changed. Consequently, a suitable pharmaceutical preparation with the active ingredient NAD or the diastereomer thereof ß-NAD is provided as a medicine against diseases which are accompanied by a constriction of the airway musculature.

Classes IPC  ?

• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61P 11/06 - Antiasthmatiques
• A61P 11/08 - Bronchodilatateurs

Abrégé

The development relates to coating glass with thermochromic vanadium dioxide. The coloration of the vanadium dioxide is shifted from bronze to neutral (colourless) by doping with earth-alkaline elements, e.g. Ca, Sr, Ba. At the same time, the thermochromic effect is maintained.

Classes IPC  ?

• C03C 17/34 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement avec au moins deux revêtements ayant des compositions différentes

Abrégé

The present invention relates to compounds derived from steroids of the general formula (I) # represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).

Classes IPC  ?

• C07J 11/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, non substitués en position 3
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle

Abrégé

The present invention relates to heterojunctions, more particularly for use as p-n diodes, the production thereof, and photovoltaic solar cells built therefrom. The heterojunction has Cu20, Cu403 or CuO, which forms the p-type part of the diode as an absorber layer. The n-type part of the diode has (Al, In)GaN in a Cu2O absorber layer, and/or (Al, In)GaN or ZnO-based systems (such as MgZnO, BeZnO) in Cu4O3 and CuO absorber layers. These p-type and n-type parts can form a tandem solar cell. Cu2O, Cu4O3 and/or CuO are produced by means of a sputtering process using an oxygen flow in plasma.

Classes IPC  ?

• H01L 31/0336 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, des matériaux semi-conducteurs couverts par plusieurs des groupes dans des régions semi-conductrices différentes, p.ex. des hétéro-jonctions Cu2X/CdX, X étant un élément du groupe VI de la classification périodique
• H01L 31/072 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV] caractérisés par au moins une barrière de potentiel ou une barrière de surface les barrières de potentiel étant uniquement du type PN à hétérojonction
• H01L 31/0725 - Cellules solaires à jonctions multiples ou dites "tandem"

Abrégé

The invention relates to a tin-enriched adhesive system for treating hypersensitive teeth and for bonding composites and ceramics to the hard tooth tissue, in particular for improved adhesion of composites, ceramics, and other dental materials on teeth that have previously experienced erosion and coating materials specifically indicated for erosion/tooth wear.

Classes IPC  ?

• A61K 6/00 - Préparations pour la technique dentaire

Abrégé

The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/81 - Inhibiteurs de protéase
• A61K 38/55 - Inhibiteurs de protéases
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The invention describes chimeric nucleases consisting of a DNA binding site derived from a TALE protein, a linker, and a cleavage module derived from a restriction endonuclease which are used for gene targeting efforts. The chimeric nucleases according to the invention exhibit increased preference and specificity to bipartite or tripartite DNA target sites comprising TALE recognition site(s) and restriction endonuclease target site while cleaving at off-target sites comprising only the restriction endonuclease target site is prevented.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

A process for producing a beverage or a beverage base, in which a medium is fermented in at least one fermentation process, in which the medium is pumpable, and in which the fermentation process is performed aerobically, the medium being fermented by mycelium of at least one basidiomycete.

Classes IPC  ?

• A23L 2/00 - Boissons non alcooliséesCompositions sèches ou concentrés pour les fabriquer Leur préparation ou leur traitement
• C12C 11/00 - Procédés de fermentation de la bière
• C12G 3/00 - Préparation d'autres boissons alcoolisées
• C12G 3/02 - Préparation d'autres boissons alcoolisées par fermentation

Abrégé

The present invention provides bio-compatible nano-polymer particles which consist of a bio-compatible polymer, a stabiliser and an active ingredient for the treatment of pulmonary hypertension or erectile dysfunction and can be used to produce an agent for the treatment of pulmonary hypertension or erectile dysfunction.

Classes IPC  ?

• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles

Abrégé

The present invention provides stabilisers for coating bio-compatible nano and microparticles, said stabilisers preventing particles from aggregating during production and storage, as well as before and during nebulisation. The stabilisers can be used to produce an agent for pulmonary application.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 9/12 - AérosolsMousses

Abrégé

The invention relates to a device and to a method for obtaining sperm from animals, in particular from birds such as parrots.

Classes IPC  ?

• A61D 19/02 - Instruments ou procédés pour la reproduction ou la fertilisation pour l'insémination artificielle

Abrégé

The invention relates to steroid-derived compounds of general formula (I) wherein L is a linker and R# is a steroid group, and to the use of the compounds of general formula (I) in medicine and for the prophylaxis and/or treatment of infectious diseases. The invention also relates to pharmaceutical compositions containing at least one compound of general formula (I), and to the synthesis of the compounds of general formula (I).

Classes IPC  ?

• C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61P 31/04 - Agents antibactériens
• A61P 31/10 - Antifongiques
• A61P 31/12 - Antiviraux
• A61P 33/00 - Agents antiparasitaires

Abrégé

The present invention relates to tripodal catechol derivatives having a flexible basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The central atom of the flexible frameworks is a tertiary aliphatic carbon atom. The remaining fourth bridgehead position can easily be further functionalized further by so-called click reactions, for example by using biomolecules, dyes, radio markers, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-C[(CH2)n-YZ]3, wherein X represents a group -(CH2)p-R5, in which p = 0-10 and R5 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R6, Y represents -CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR1-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR1-(C=O)-, -(C=O)-NR1-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents an alkyl group, R6 represents an alkyl, alkenyl, alkinyl, aryl or heteroaryl group and Z represents a catechol derivative. The compounds are produced by reacting a compound X-C[(CH2)n-Y']3 with a reagent Y"Z to form the corresponding compound X-C[(CH2)n-YZ]3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

Classes IPC  ?

• C07C 231/02 - Préparation d'amides d'acides carboxyliques à partir d'acides carboxyliques ou à partir de leurs esters, anhydrides ou halogénures par réaction avec de l'ammoniac ou des amines
• C07C 235/32 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons

Abrégé

The present invention relates to tripodal catechol derivatives having an adamantyl basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The remaining fourth bridgehead position can easily be further functionalized by so-called click reactions, for example by using biomolecules, dyes, radio markers, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-Ad[(CH2)n-YZ]3, wherein Ad represents the adamantyl basic framework, X represents a group -(CH2)p-R5, in which p = 0-10 and R5 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R6, Y represents -CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR1-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR1-(C=O)-, -(C=O)-NR1-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents an alkyl group, R6 represents an alkyl, alkenyl, alkinyl, aryl or heteroaryl group and Z represents a catechol derivative. The compounds are produced by reacting a compound X-Ad[(CH2)n-Y']3 with a reagent Y"Z to form the corresponding compound X-Ad[(CH2)n-YZ]3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

Classes IPC  ?

• C07C 231/02 - Préparation d'amides d'acides carboxyliques à partir d'acides carboxyliques ou à partir de leurs esters, anhydrides ou halogénures par réaction avec de l'ammoniac ou des amines
• C07C 235/46 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques

Abrégé

The present invention relates to tripodal bisphosphonate derivatives having an adamantyl basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The remaining fourth bridgehead position of the adamantane framework can optionally be functionalized by so-called click reactions, for example by using biomolecules, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-Ad{(CH2)n-Y-C[PO(OH)2]2R1}3, wherein Ad represents the adamantyl framework, X represents a group -(CH2)p-R3, in which p = 0-10 and R3 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R4, Y represents -CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR2-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR2-(C=O)-, -(C=O)-NR2-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents a hydrogen atom or a hydroxy group, R2 represents a linear or branched alkyl group, and R4 represents a linear or branched alkyl or aryl group. The compounds are produced by reacting a compound X-Ad[(CH2)n-Y']3 with a reagent Y"C[PO(OH)2]2R1 to form the corresponding compound X-Ad{(CH2)n-Y-C[PO(OH)2]2R1}3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

Classes IPC  ?

• C07F 9/38 - Acides phosphoniques [R—P(:O)(OH)2]Acides thiophosphoniques

Abrégé

The present invention relates to tripodal bisphosphonate derivatives having a flexible basic framework for functionalizing surfaces, to methods for the production and to the use thereof. The central atom of the flexible frameworks is a tertiary aliphatic carbon atom. A remaining fourth bridgehead position of the flexible framework can optionally be functionalized by so-called click reactions, for example by using biomolecules, polyethylene glycol or active substances. The compounds according to the invention have the general formula X-C{(CH2)n- Y-C[PO(OH)2]2R1}3, wherein X represents a group -(CH2)p-R3, in which p = 0-10 and R3 is selected from -H, -NH2, -NO2, -OH, -SH, -O-NH2, -NH-NH2, -N=C=S-, -N=C=O-, -CH=CH2, -C=CH, -COOH, -(C=O)H, -(C=O)R4, Y represents CH2-, -CH=CH-, -C=C-, -O-, -S-, -S-S-, -NH-, -O-NH-, -NH-O-, -HC=N-O-, -O-N=CH-, -NR2-, -aryl-, -heteroaryl-, -(C=O)-, -O-(C=O)-, -(C=O)-O-, -NH-(C=O)-, -(C=O)-NH-, -NR2-(C=O)-, -(C=O)-NR2-, -NH-(C=O)-NH-, -NH-(C=S)-NH-, R1 represents a hydrogen atom or a hydroxy group, R2 represents a linear or branched alkyl group, and R4 represents a linear or branched alkyl or aryl group. The compounds are produced by reacting a compound X-C[(CH2)n-Y']3 with a reagent Y"C[PO(OH)2]2R1 to form the corresponding compound X-C{(CH2)n-Y-C[PO(OH)2]2R1}3 and the reaction product is subsequently purified. Y' and Y'' are precursors of Y. The compounds according to the invention of formula (I) can be used in a method for functionalizing surfaces. Optionally, the group X of the compounds according to the invention can be coupled to an effector, for example by means of click chemistry.

Classes IPC  ?

• C07F 9/38 - Acides phosphoniques [R—P(:O)(OH)2]Acides thiophosphoniques

Abrégé

The invention relates to a method for producing a p-conductive semiconductor layer containing ZnO, comprising the supply of a gaseous nitrogen/hydrogen compound to a reactor during the deposition of the semiconductor layer (S32) containing ZnO, the adsorption of the nitrogen/hydrogen compound on a respective current growth surface of the semiconductor layer (S34) containing ZnO, and the formation of a nitrogen/hydrogen complex in the semiconductor containing ZnO as an acceptor structure which effects p-conductivity using the adsorbed nitrogen/hydrogen compound (S36).

Classes IPC  ?

• H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
• H01L 21/20 - Dépôt de matériaux semi-conducteurs sur un substrat, p. ex. croissance épitaxiale

Abrégé

The invention comprises peptide or non-peptide receptor agonists of the natriuretic system, preferably NPRA and NPRB receptor agonists for the prevention and/or therapy of disease conditions which are accompanied by increased extracellular liquid volume and in which the second messenger cGMP develops protective properties and in which an anti-hypertrophic (antifibrotic) effect is desired. The invention in particular relates to peptide or non-peptide receptor agonists of the natriuretic system for treating congestive heart disease, coronary heart disease, organ and functional vascular disorders, nephrotic syndrome, high blood pressure, myocardial infarction, acute pulmonary damage, erectile dysfunction, primary or secondary fibrosis, cirrhosis of the liver, pulmonary fibrosis or for improving blood circulation of the arteries, veins and capillaries.

Classes IPC  ?

• A61K 38/22 - Hormones
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The invention relates to biocompatible nano-, meso-, and micro-polymer particles which can bind pathogenic proteins that penetrate into the lining layer of the lung. Known pathogenic proteins in the pulmonary lining layer are negatively charged. Said proteins damage the pulmonary surfactant system, which is essential for maintaining a low surface tension in the lung and thus for functional breathing. Polymer particles according to the invention have a diameter between 20 nm and 10 pm, are water-insoluble, and have a positive surface charge and a low surface hydrophobicity. The isoelectric point of the particles is greater than 5, so that the particles are present in the lining layer of the lung as positively charged particles, and also greater than the isoelectric point of the pathogenic proteins to be bound. The polymer particles according to the invention can be produced by means of precipitation or emulsion methods for example. The polymer particles according to the invention can be used for maintaining a low surface tension in the lung and for protecting the pulmonary surfactant.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/51 - Nanocapsules
• A61K 31/78 - Polymères contenant de l'oxygène d'acide acrylique ou de ses dérivés
• A61K 31/785 - Polymères contenant de l'azote
• C08L 33/14 - Homopolymères ou copolymères des esters d'esters contenant des atomes d'halogène, d'azote, de soufre ou d'oxygène en plus de l'oxygène du radical carboxyle

Abrégé

The invention relates to the use of NOS inhibitors, such as L-NIL, for producing an agent for treating and/or preventing chronic pulmonary diseases in humans.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 11/06 - Antiasthmatiques
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The disclosed invention relates to peptides incorporating 3-aminoadamantane-1-carboxylic acids. These peptides are disclosed as surprisingly possessing neurogenic and neurotrophic properties. These pharmacological activities can advantageously be utilized for restoring or maintaining neuronal function in the CNS. In particular, the compounds can be used for treatment and prophylaxis of neurodegenerative diseases, e. g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, as well as in post-acute traumatic brain injury, or cerebral ischemia.

Classes IPC  ?

• C07K 7/02 - Peptides linéaires contenant au moins une liaison peptidique anormale
• C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present invention relates to a method and an apparatus for determining the concentration of protamine 1 and protamine 2 and the ratio of protamine 1 to protamine 2 as a protamine/protein ratio in a questionable sample from an individual to be examined in vitro in order to determine the fertility of sperm. This is very important for the prognosis for the success of artificial insemination of an egg cell in vitro. The test strip has a sperm pretest for determining the sperm concentration and a protamine rapid test for determining the concentration of protamine 1 and protamine 2 and the ratio of protamine 1 to protamine 2 as a protamine/protein ratio.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention pertains to an inhibitor molecule that is capable of inhibiting the activity of miR17, miR21 or miR92a in a cell for the purpose of treating pulmonary hypertension as well as to a pharmaceutical composition for treating pulmonary hypertension.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

The present invention relates to a method for the diagnosis, early detection and/or risk stratification of pulmonary hypertonism in a patient and/or monitoring a therapy of such a disease in a patient, comprising the quantitative determination of at least one component of the vascular endothelial growth factor (VEGF) signal pathway as biomarker, in particular the quantitative determination of the biomarkers soluble Fms-like tyrosine kinase-1 (sFlt) and/or placental growth factor (PIGF). The invention furthermore relates to a diagnostic kit for carrying out the method according to the invention, and to its use.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

Classes IPC  ?

• C07K 14/81 - Inhibiteurs de protéase
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to a device for spreading active agricultural agents, wherein the device can be brought to the site of action temporally and spatially separated from the production process and comprises a dispenser as well as non-water-soluble nanofibers and/or mesofibers storing active agricultural agents. The polymers of which the nanofibers or mesofibers consist are preferably biodegradable. The active agricultural agents are selected from the group consisting of fungicides, herbicides, bactericides, plant growth regulators and plant nutrients. They are preferably pheromones, kairomones, and signal substances. The invention further discloses a method for producing said device, wherein the nanoparticles and/or mesofibers storing active agents are produced by means of electrospinning. The device can be used to bring active agricultural agents to the site of action thereof temporally and spatially separated from the production process. The spreading can be done mechanically or automatically. The site is preferably a useful area from pomiculture, viticulture, horticulture or a commercial row crop. The device according to the invention is particularly suited for controlling arthropods.

Classes IPC  ?

• D01F 1/10 - Autres agents modifiant les propriétés de ces filaments
• D01F 6/84 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiquesLeur fabrication à partir de produits de copolycondensation à partir de copolyesters
• D01D 5/00 - Formation des filaments, fils ou similaires
• A01N 25/10 - Composés macromoléculaires
• A01N 25/34 - Formes façonnées, p. ex. feuilles, non prévues dans l'un quelconque des autres sous-groupes du présent groupe principal
• A01G 13/02 - Couvertures protectrices pour les plantes; Dispositifs pour leur mise en place

Abrégé

The current invention relates to a method of making metal oxide nanoparticles comprising the reaction of - at least one metal oxide precursor (P) containing at least one metal (M) with - at least one monofunctional alcohol (A) wherein the hydroxy group is bound to a secondary, tertiary or alpha-unsaturated carbon atom - in the presence of at least one aliphatic compound (F) according to the formula Y1-R1-X-R2-Y2, wherein - R1 and R2 each are the same or different and independently selected from aliphatic groups with from 1 to 20 carbon atoms, - Y1 and Y2 each are the same or different and independently selected from OH, NH2 and SH, and - X is selected from the group consisting of chemical bond, -O-, -S-, -NR3-, and CR4R5, wherein R3, R4 and R5 each are the same or different and represent a hydrogen atom or an aliphatic group with from 1 to 20 carbon atoms which optionally carries functional groups selected from OH, NH2 and SH. This invention also relates to metal oxide nanoparticles, to a method of making dispersions of said nanoparticles and to dispersions containing them.

Classes IPC  ?

• C01G 1/02 - Oxydes
• C01G 15/00 - Composés du gallium, de l'indium ou du thallium
• C01G 19/02 - Oxydes
• C01G 21/02 - Oxydes
• C01G 23/047 - Dioxyde de titane
• C01G 25/02 - Oxydes
• C01G 30/00 - Composés de l'antimoine
• C01G 31/02 - Oxydes
• C01G 33/00 - Composés du niobium
• C01G 35/00 - Composés du tantale
• C01G 37/02 - Oxydes ou leurs hydrates
• C01G 45/02 - Oxydes
• C01G 49/02 - OxydesHydroxydes

Abrégé

The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 µm and 5 µm, preferably between 0.2 µm and 2.0 µm, and the median aerodynamic mass diameter of aerosol particles comprising the liposomes is between 1 µm and 6 µm, preferably between 1.5 µm and 5 µm, in particular preferably between 2 µm and 4.5 µm. It is further in particular advantageous if the liposomes comprise an atomization stability of greater than 50%, preferably greater than 75%, in particular preferably greater than 80%, and if the transition temperature is greater than 37 °C, preferably greater than 45 °C, in particular preferably greater than 50 °C.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique

Abrégé

The invention relates to a novel method and a novel device for annealing scintillation crystals that reduces the damage thereto by effect of radiation in terms of a reduction of the optical transparency. For the first time, such damage has been completely healed quasi on-line, i.e. at the same time as the damage occurred, so that reduction of the optical transparency is no longer observable during the operation of said crystals.

Classes IPC  ?

• G01T 1/202 - Mesure de l'intensité de radiation avec des détecteurs à scintillation le détecteur étant du cristal

Abrégé

The present invention relates to a device and a method for removing, producing, storing, and transporting blood products in the widest sense, in particular a closed blood removal, processing, and storage system, and a system for administering drugs that are obtained from blood or blood products and a corresponding method for obtaining, producing, storing, and transporting blood products or blood components or blood constituents or blood preparations (within the meaning of the Medical Products Act AMG) in a legally compliant and GMP-compliant manner. In an exceptional manner, the present invention enables the production, storage, transport, and administration of completely aliquoted autologous serum eye drops or other drugs from blood or blood products that can be applied to the patient directly without the need for clean-room laboratories.

Classes IPC  ?

• A61M 1/02 - Appareils pour transfusion sanguine d'un corps à un autre
• A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration

Abrégé

The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 µm and lengths of 1 µm to several meters. The invention further relates to a method for producing said composite materials. Polymer nanoparticles can be produced in different ways, such as through controlled precipitation of a polymer solution that optionally comprises a loading substance. The nanoparticles are then mixed with another polymer and a loading substance as applicable, depending on whether particles, fibers or both are to be loaded with substance. The processing of this solution into composites comprising polymer fibers polymer nanoparticles can occur by means of electrospinning, melt spinning, extruding or template process. Composite materials according to the invention are suitable for the production of pharmaceuticals that release therapeutically or diagnostically effective substances slowly and in a controlled manner.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 9/70 - Bases pour bande, feuille ou filament

Abrégé

The invention relates to an occlusion implant (1) for occluding a blood vessel (19). The implant (1, 24) comprises a wire (5) that is wound to form a helical coil (2, 3, 25, 29). The coil has a first pitch over wide areas (7). However, in at least one second area (9), the coil (2, 3, 25, 29) has a second pitch that differs from the first pitch.

Classes IPC  ?

• A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical

Abrégé

The present invention relates to an agent for the prophylaxis and treatment of pityriasis. The agent according to the invention comprises at least one transaminase inhibitor that effectively inhibits the development of the transamination process that is pathogenetically significant to the disease, prevents a recurrence of the disease, and is easy on the skin flora of humans. Upon entry into the environment, resistances are not induced in other fungi.

Classes IPC  ?

• A61K 31/15 - Oximes (C=N-O-)Hydrazines ( N-N)Hydrazones (N-N=)
• A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
• A61K 31/42 - Oxazoles
• A61K 31/52 - Purines, p. ex. adénine
• A61K 31/7008 - Composés ayant un groupe amino lié directement à un atome de carbone du radical saccharide, p. ex. D-galactosamine, ranimustine
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 31/10 - Antifongiques

Abrégé

The invention relates to the use of ribosomal protein S19 (symbol: RPS19, HGNC ID:10402, alias: DBA), which inhibits the proinflammatory and procarcinogenic effects of MIF, as a material for producing a means for treating acute and chronic inflammatory diseases and cancer diseases.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with Complex Regional Pain Syndrome, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides - especially in apheresis and in vitro assays- for the treatment and the diagnosis of Complex Regional Pain Syndrome.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to an immunological test for detecting and for specifically determining autoantibodies against testicular antigens that accompany inflammatory fertility disorders of male mammals in a biological sample of a male mammal, particularly for detecting testicular ER-60 autoantibodies and/or transferrin autoantibodies. The immunological test is used to determine the presence of immunological and infection-related infertility of male mammals, particularly of humans.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 9/90 - Isomérases (5.)

Abrégé

The invention relates to a method for the specific and early detection of a Mycobacterium avium ssp. paratuberculosis (MAP) infection in a biological sample of a mammal by detecting cells producing interferon-gamma (IFN-γ) after incubating peripheral blood mononuclear cell cultures (PBMC) with MAP antigen preparations or Mycobacterium avium ssp. avium (MAA) and/or Mycobacterium phlei (M. phlei) control antigens.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method and a test kit for the specific and sensitive detection of antibodies against Mycobacterium avium ssp. paratuberculosis (MAP) in biological samples. The method and the test kit are also used to detect antibodies against Mycobacterium tuberculosis or Mycobacterium bovis.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The invention relates to functionalised diols of diamondoids wherein one of the two hydroxy groups is masked by a protective group, and to methods for producing said functionalised diols. The protective group is a -CHR1R2 group, wherein R1 and R2 are alkyl groups. The protective group contains at least one halogen atom. The monoethers of the diamondoid diols are produced by reacting the diamondoid diol with a halogenated alcohol CHOHR1R2 in the presence of a catalyst acid. The monoetherified diols enable the targeted production of derivatives of the diamondoids, for example the corresponding amino alcohols and aminocarboxylic acids. To this end, the diamondoid monoether is reacted with a halogenonitrile in a Ritter reaction, in a first step, to form the corresponding monoether amide. The corresponding amino alcohol is produced from said monoether amide by reacting the protective group -CHR1R2 first with trifluoroacetic acid to form the alkanoyloxy group, and then obtaining the amino alcohol by reaction with thiourea, ethanol and glacial acetic acid. The amino alcohol can be reacted with sulphuric acid / formic acid or fuming sulphuric acid / formic acid to form the corresponding amino carboxylic acid. The amino, hydroxy, and carboxyl groups of the diamondoids can be converted into a plurality of other functional groups.

Classes IPC  ?

• C07C 41/09 - Préparation d'éthers par déshydratation de composés contenant des groupes hydroxyle
• C07C 43/196 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle autre que ceux d'un cycle aromatique à six chaînons contenant des groupes hydroxyle ou O-métal
• C07C 205/18 - Composés contenant des groupes nitro liés à un squelette carboné le squelette carboné étant substitué de plus par des groupes hydroxy ayant des groupes nitro ou des groupes hydroxy liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons
• C07C 213/02 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions impliquant la formation de groupes amino à partir de composés contenant des groupes hydroxy ou des groupes hydroxy éthérifiés ou estérifiés
• C07C 215/42 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes amino ou des groupes hydroxy liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné
• C07C 217/52 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés ou des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné
• C07C 227/02 - Formation de groupes carboxyle dans des composés contenant des groupes amino, p. ex. par oxydation d'amino-alcools
• C07C 229/50 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino ou carboxyle liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et des groupes carboxyle liés à des atomes de carbone faisant partie du même système cyclique condensé
• C07C 231/06 - Préparation d'amides d'acides carboxyliques à partir de nitriles par transformation de groupes cyano en groupes carboxamide
• C07C 233/23 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons

Abrégé

The present invention relates to novel monoether derivatives of diols, the OH groups thereof being located in the 2 position of carbon atoms with π electron pairs, and a method for the production thereof. The monoether derivatives according to the invention are diols in which one of the two OH groups is etherized with a -CHR1 R2 protective group. R1 is an alkyl group, R2 stands for hydrogen or an alkyl group. The protective group contains at least one halogen atom, preferably fluorine. The mono-etherized diols make targeted production of derivatives of such diols whose OH groups are located in the 2 position of carbon atoms with π electron pairs possible. For example, the corresponding amino alcohols and amino carboxylic acids of benzyl, allyl and propargyl diols can be produced in this way in targeted fashion.

Classes IPC  ?

• C07C 43/178 - Éthers non saturés contenant des groupes hydroxyle ou O-métal
• C07C 41/09 - Préparation d'éthers par déshydratation de composés contenant des groupes hydroxyle

Abrégé

The invention relates to a method for producing a conductor/non-conductor transition on a substrate (1), the substrate (1) comprising a non-conductive metal oxide layer (2), wherein the non-conductive metal oxide layer (2) is made of metastable amorphous non-stoichiometric metal oxide (2) and is locally heated, wherein the locally heated region crystallizes into a stable non-conductive stoichiometric metal oxide (4), around which the metal concentration in the amorphous non-stoichiometric metal oxide increases, in particular forms a conductive region (5). The invention further relates to a storage medium for storing digital information, comprising a particularly round rotatable substrate (1) and a layer (2) disposed thereon for receiving digital information, wherein the layer (2) is configured by a non-conductive amorphous non-stoichiometric metal oxide, which can be transferred by means of local heating, particularly using a focused laser beam (3a, 3b) or an electron beam or a current pulse, at the location of the local heating into a region (4) made of crystallized, non-conductive stoichiometric metal oxide, which is surrounded by an increased metal concentration, particularly amorphous conductive non-stoichiometric metal oxide (5). The invention also relates to a method for producing an amorphous non-conductive non-stoichiometric metal oxide layer on a substrate (1), wherein the non-stoichiometric metal oxide layer (2) is removed from a target of the same metal oxide present in a stoichiometric form, and deposited onto the substrate.

Classes IPC  ?

• G11B 7/0045 - Enregistrement
• G11B 7/242 - Supports d’enregistrement caractérisés par le choix du matériau des couches d'enregistrement

Abrégé

The present invention relates to a pharmaceutical, or to a process for the preparation of a pharmaceutical, for the treatment of fibrosing pulmonary diseases, in particular idiopathic pulmonal fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). This involves using an agent which brings about a correction of the maladaptive ER stress response, which occurs in the alveolar type-II cells, or the blocking of the epithelial apoptosis.

Classes IPC  ?

• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The present invention relates to Cu-(ll)-oxygen adduct complexes, which are stable at room temperature, and to methods for the production thereof. These are compounds of the general formula [L-Cu-O-O-Cu-L](BAr4)2. To this end, BAr4 is a tetraarylborate anion, selected from tetraphenylborate and tetrakis(3,5-trifluoromethyl)phenylborate. L is a tripodal tetradentate ligand, wherein each of the four binding sites can be a nitrogen atom. Each of the three podal ligands, independently from each other, may comprise an aliphatic amine or a nitrogen-containing heteroaromat. Between the central nitrogen atom and the nitrogen atom of each of the podal ligands, a bridge comprising one to four carbon atoms is present. The Cu(ll)-oxygen adduct complexes according to the invention are produced in that first the ligand L is reacted into [Cu-L]X using a Cu-(I) salt. Then, the anion X of the Cu-(l) complex [Cu-L]X is replaced with tetraarylborate, and the compound [Cu-L]BAr4 that is obtained is finally subjected to an oxygen-containing atmosphere. In this process, [L-Cu-O-O-Cu- L](BAr4)2 forms. The Cu-(ll)-oxygen adduct complexes according to the invention can be used as oxidation catalysts, for example for the oxidation of benzene into phenol or methane, for the oxidation of hydrogen, aromatic and aliphatic, saturated and unsaturated hydrocarbons and also alcohols and amines. Furthermore, the verification of the Cu-(ll)-oxygen adduct complexes according to the invention can be used for the detection of oxygen.

Classes IPC  ?

• C07F 1/08 - Composés du cuivre
• C07F 5/02 - Composés du bore

Abrégé

The present invention relates to an immortalized keratinocyte cell line from the gingiva and a cell culture system in which the cell line is used in order to test the effect of protective and/or modifying substances (such as anti-infectives, oral hygiene products) on the epithelial function of the gingiva/periodontium under in vitro conditions. The cells were infected with germs of the oral cavity and the effect of the potentially protective and/or modifying substances on the cells was measured, for example, by the change of the transepithelial electric resistance (TEER). The invention thereby replaces animal experiments and allows an analysis in high through-put.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The invention relates to the production, specific expression and permanent secretion of canine interleukins, especially interleukin-2 (clL-2) or interleukin-12 (clL-12) from transfected BHK-Tet-On cells and to the use of the lymphokine-activated killer cells produced thereby in the tumor therapy of dogs.

Classes IPC  ?

• C12P 21/00 - Préparation de peptides ou de protéines

Abrégé

The invention relates to a method for specifically and sensitively detecting Mycobacterium avium ssp. paratuberculosis (MAP) in excrement, tissue, and organ samples by means of a real-time PCR process.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention describes a method for the verification of cholinergic neurons in tissue samples from a human or animal organism by detection of the SLC10A4 protein. SLC10A4 occurs exclusively in cholinergic neurons. In a preferred embodiment of the present invention, oligopeptides of the C-terminus of SLC10A4 are used to form polyclonal antibodies. For this purpose, the 422-437 amino acids of the SLC10A4 protein are coupled to the carboxy-terminal glutamic acid group on KLH. The protein that has been KLH-coupled in this manner is subsequently injected into a vertebrate, which subsequently forms polyclonal antibodies against SLC10A4. Polyclonal antibodies against SLC10A4 obtained in this manner are used according to the invention for detecting SLC10A4 in cholinergic neurons, for example, with the aid of the sandwich method in which, after incubation with the antibody according to the invention, an arbitrary second antibody is added by means of which the P4 protein is made optically visible. The visualization of SLC10A4 may occur, for example, by means of immunofluorescence or peroxidase staining.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention encompasses a cell line from the maternal portion of the placenta of pregnant bovine animals which undergoes permanent culture (BCEC Bovine Caruncular Epithelial Cells cell line) and is used in various in vitro assays inter alia for detecting the activity of substances on the epithelial barrier between maternal and fetal portion. The cell line is negative for the BVD virus and is also employed as in vitro assay for BVD infection studies.

Classes IPC  ?

• C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention provides a method which is simple and easy to carry out for inducing insulin synthesis in isolated chorion cells which are obtained from the amnion. The cells are stimulated to insulin synthesis by the addition of L gastrin and GLP-1 or exendin-4, wherein a large quantity of insulin is released. The cells and the method for inducing insulin synthesis are thus suitable for the production of a means for treating diabetes mellitus.

Classes IPC  ?

• C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux

Abrégé

The invention relates to methods for producing particles comprising metals, semiconductors, metallic compounds or semiconductor compounds with diameters in the nanometer range. According to said methods, an electrochemically reducible precursor substance is dissolved in an ionic liquid, and is either reduced by free electrons in a plasma phase or is reacted with particles from the plasma phase. The particles obtained by the inventive method can be used, for example, as additives for polymers for coating medical instruments or as electrochemical catalysts. The particles can optionally be bound to or onto a substrate.

Classes IPC  ?

• B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage
• B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
• B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles

Abrégé

The invention relates to 1-formamido-adamantane derivatives of formula (I), which carry the substituents R1, R2 or R3 in 3, 5 and/or 7 position, the substituents being defined as follows: hydrogen, a linear or branched alkyl, alkenyl or alkinyl group with up to 6 C atoms, an aliphatic or aromatic, cyclic or heterocyclic hydrocarbon group with up to 10 carbon atoms, and formamides of hydrocarbons from the group of diamondoids, for example diamantane, triamantane, tetramantane and pentamantane, however, with the exception of 1-formamido-3,5-dimethyladamantane. The invention also relates to a method for the direct formation of formamide or acetamide of adamantane, adamantane derivatives with the aforementioned definition of substituents or of a hydrocarbon from the group of diamondoids, characterized by reacting the adamantane, the adamantane derivative or the diamondoid with formamide, acetamide or acetonitrile in concentrated acids, while avoiding SO3 containing sulfuric acid or 100% azotic acid.

Classes IPC  ?

• C07C 233/03 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués avec des atomes de carbone de groupes carboxamides liés à des atomes d'hydrogène
• C07C 231/08 - Préparation d'amides d'acides carboxyliques à partir d'amides par réaction sur les atomes d'azote de groupes carboxamide

Abrégé

The invention relates to at least dinitroxylated diamantanes, and to methods by which means a high yield and selectivity of substituted diamantanes can be produced. According to the invention, dinitroxylated diamantanes can be reacted with nucleophiles to form the corresponding disubstituted diamantanes. Surprisingly, it was discovered that at least dinitroxylated or hydroxylated diamantanes are rearranged in the presence of a strong acid, creating at least 4,9-nitroxylated or hydroxylated diamantanes. On the basis of this, 4,9-substituted diamantanes can be produced in a targeted manner by reaction with other nucleophiles. The inventive methods for producing at least disubstituted diamantanes consist of the following steps: a) at least dinitroxylation, followed by substitution of all of the nitroxy groups with a nucleophile, or b) at least dinitroxylation, then rearrangement in the presence of a strong acid, all nitroxy groups being replaced by a nucleophile in the event of a successful rearrangement, or c) at least dinitroxylation, followed by a reaction with water (as nucleophile), and rearrangement of the at least dihydroxylated compound in the presence of a strong acid, all hydroxy groups being replaced by another nucleophile in the event of a successful rearrangement.

Classes IPC  ?

• C07C 13/615 - Adamantanes
• C07C 23/46 - Hydrocarbures halogénés polycycliques à cycles condensés dont aucun n'est aromatique à plus de trois cycles condensés

Abrégé

The invention relates to a novel class of gas sensors for hydrogen or fluids (gases or liquids) containing hydrogen, such as hydrocarbons, hydrogen sulfides, or more complex gas mixtures or gas compositions containing hydrogen or hydrogen compounds. Both the reflection coefficient of the functional layer of the sensor and the change in the resistance of said layer are determined by means of one and the same sensor. The functional layer contains Mg and Ni or Mg and Al in an amorphous and/or microcrystalline and/or partly polycrystalline form.

Classes IPC  ?

• G01N 21/55 - Réflexion spéculaire
• G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de l'absorption d'un fluideRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide

Abrégé

The invention relates to a rapid, safe method for predicting sepsis or a condition similar to sepsis, wherein clinical and genomic data is correlated in an optimal manner with expression profile special genes which is issued from the blood of patients.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques